We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Interpace Biosciences Inc | NASDAQ:IDXG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.92 | 3.90 | 4.01 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
PARSIPPANY, N.J., Feb. 10, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (IDXG) ("Interpace" or the "Company"), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced that its President & Chief Executive Officer, Jack E. Stover, will deliver a corporate presentation at the 2017 BIO CEO & Investor Conference, being held February 13-14, 2017 at the Waldorf Astoria Hotel in New York.
Details for this presentation are as follows:
A live webcast of Interpace Diagnostics' presentation may be accessed by logging onto the internet at http://www.veracast.com/webcasts/bio/ceoinvestor2017/69132493167.cfm. A replay will be archived and accessible for 90 days at the same website.
About Interpace Diagnostics Group
Interpace is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests: PancraGEN®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace's mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information, please visit Interpace Diagnostics' website at www.interpacediagnostics.com.
CONTACTS:
Victor Roberts
RedChip Companies
407.644.4256, ext. 111
victor@redchip.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/interpace-diagnostics-to-present-at-2017-bio-ceo--investor-conference-300405706.html
SOURCE Interpace Diagnostics Group, Inc.
Copyright 2017 PR Newswire
1 Year Interpace Biosciences Chart |
1 Month Interpace Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
